REM-422

Near Add Your Location

Sorting 1 by

Accepting patients

REM-422

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS
Learn more
  • MYB mRNA Degrader
  • Phase 1